Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure

NCT02917031 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02917031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02917031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
January 10, 2017
Completion date
August 23, 2019
Enrollment
348 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, type 2 diabetes mellitus